Fresenius Kabi (Adalimumab Biosimilar) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Fresenius Kabi (Adalimumab Biosimilar) General Information

Description

Medicine formula is located in Homburg, Germany.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Homburg
  • Germany
Primary Industry
Buildings and Property
Corporate Office
  • Homburg
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fresenius Kabi (Adalimumab Biosimilar) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Fresenius Kabi (Adalimumab Biosimilar)‘s full profile, request access.

Request a free trial

Fresenius Kabi (Adalimumab Biosimilar) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Fresenius Kabi (Adalimumab Biosimilar)‘s full profile, request access.

Request a free trial

Fresenius Kabi (Adalimumab Biosimilar) FAQs

  • Where is Fresenius Kabi (Adalimumab Biosimilar) headquartered?

    Fresenius Kabi (Adalimumab Biosimilar) is headquartered in Homburg, Germany.

  • What industry is Fresenius Kabi (Adalimumab Biosimilar) in?

    Fresenius Kabi (Adalimumab Biosimilar)’s primary industry is Buildings and Property.

  • Is Fresenius Kabi (Adalimumab Biosimilar) a private or public company?

    Fresenius Kabi (Adalimumab Biosimilar) is a Private company.

  • What is Fresenius Kabi (Adalimumab Biosimilar)’s current revenue?

    The current revenue for Fresenius Kabi (Adalimumab Biosimilar) is .

  • Who are Fresenius Kabi (Adalimumab Biosimilar)’s investors?

    Fresenius Kabi has invested in Fresenius Kabi (Adalimumab Biosimilar).

  • When was Fresenius Kabi (Adalimumab Biosimilar) acquired?

    Fresenius Kabi (Adalimumab Biosimilar) was acquired on 01-Oct-2024.

  • Who acquired Fresenius Kabi (Adalimumab Biosimilar)?

    Fresenius Kabi (Adalimumab Biosimilar) was acquired by Evio (Enterprise Systems).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process